Press release from Companies
Publicerat: 2026-03-26 07:30:00
Uppsala, Sweden – March 26, 2026 – Double Bond Pharmaceutical AB (publ) (“DBP”) announces its participation in the Karolinska Institutet (KI) Career Service Internship Program. Through this initiative, DBP will host a PhD student or Postdoctoral researcher from KI to collaborate on the advanced analysis of Real-World Evidence (RWE) for Temodex, the company’s innovative treatment for glioblastoma.
Strengthening Data Precision for Temodex
The KI program is designed to bridge the gap between high-level academic research and industrial application. For DBP, this collaboration provides access to cutting-edge expertise in medical statistics and clinical methodology.
The project focuses on the analysis and validation of DBP’s expanding RWE dataset, which comprises data from over 480 patients. Preliminary results already indicate a significant improvement in Overall Survival (OS) for patients treated with Temodex compared to current standard-of-care data.
Key Contributions to the RWE Analysis:
CEO Statement
"Collaborating with Karolinska Institutet, one of the world's leading medical universities, is a significant step for us," says Igor Lokot, CEO of Double Bond Pharmaceutical. "By integrating a high-level researcher into our team, we can apply more sophisticated analytical frameworks to our RWE dataset. This not only prepares us for our upcoming presentation at the EANS 2026 Congress in Hamburg but also solidifies the clinical evidence required to bring Temodex to the global market."
The results of this collaborative analysis are expected to be presented at the EANS 2026 Congress.
More about Career Service Internship Program: https://staff.ki.se/your-employment/careers-at-ki/company-collaboration#P302035
More about Real-World Evidence Study: https://mb.cision.com/Main/12720/4307158/3933333.pdf
More about EANS2026 Congress: https://eanscongress.org/
More about SI-053: SI-053, an enhanced reformulation of Temodex, is a locally acting formulation of temozolomide. SI-053 received Orphan Drug Designation from the European Medicines Agency in 2016 and received multiple Competent Authority and Ethics Committee approvals from 2021 to 2023 to initiate a Phase 1 clinical study. In a proof-of-concept study with human subjects conducted in 2015, SI-053 demonstrated significant overall survival benefit when added to the standard of care for glioblastoma. Video presentation: https://youtu.be/iweOQPq316o
This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-03-2026 07:30 CET.
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Follow us on LinkedIn
Information about Double Bond Pharmaceutical AB: DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.
